| MeSH term | MeSH ID | Detail |
|---|---|---|
| Cataract | D002386 | 34 associated lipids |
| Cell Transformation, Neoplastic | D002471 | 126 associated lipids |
| Myoclonic Cerebellar Dyssynergia | D002527 | 1 associated lipids |
| Brain Ischemia | D002545 | 89 associated lipids |
| Ischemic Attack, Transient | D002546 | 42 associated lipids |
| Cerebrovascular Disorders | D002561 | 25 associated lipids |
| Uterine Cervical Dysplasia | D002578 | 2 associated lipids |
| Cheilitis | D002613 | 2 associated lipids |
| Cholelithiasis | D002769 | 16 associated lipids |
| Cholestasis | D002779 | 23 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| David-Neto E et al. | Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. | 2017 | Transplantation | pmid:27798513 |
| Morrissey PE | Prope tolerance: is it the end or the means? | 2009 | Transplantation | pmid:19502973 |
| Farid SG et al. | Alemtuzumab (Campath-1H)-induced coagulopathy in renal transplantation. | 2009 | Transplantation | pmid:19502974 |
| Prókai à et al. | Calcineurin-inhibition Results in Upregulation of Local Renin and Subsequent Vascular Endothelial Growth Factor Production in Renal Collecting Ducts. | 2016 | Transplantation | pmid:26502369 |
| Egawa H et al. | FK506 conversion therapy in pediatric liver transplantation. | 1994 | Transplantation | pmid:7513911 |
| Cvetkovic M et al. | The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo. | 1994 | Transplantation | pmid:7513912 |
| Benito N et al. | Alternariosis after liver transplantation. | 2001 | Transplantation | pmid:11740399 |
| Asako H et al. | Reduction of leukocyte adherence and emigration by cyclosporine and L683,590 (FK506) in postcapillary venules. | 1992 | Transplantation | pmid:1384191 |
| Schäffer MR et al. | Tacrolimus impairs wound healing: a possible role of decreased nitric oxide synthesis. | 1998 | Transplantation | pmid:9539093 |
| Kato T et al. | Rhabdomyolysis after kidney transplantation caused by elevated serum cyclosporine due to metabolic enzyme and transporters disorder. | 2011 | Transplantation | pmid:21747275 |
| Manez R et al. | Rejection and hepatitis in liver transplants. | 1994 | Transplantation | pmid:7517080 |
| Cao W et al. | Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. | 1995 | Transplantation | pmid:7532879 |
| Soccal PM et al. | Improvement of drug-induced chronic renal failure in lung transplantation. | 1999 | Transplantation | pmid:10428288 |
| Lee CM et al. | Outcomes in diabetic patients after simultaneous pancreas-kidney versus kidney alone transplantation. | 1997 | Transplantation | pmid:9371670 |
| Migita K et al. | FK506 potentiates steroid-induced T-cell apoptosis. | 1997 | Transplantation | pmid:9371682 |
| Dhar DK et al. | Effective prevention of ischemic injury of the dearterialized canine liver by FK506 pretreatment. | 1993 | Transplantation | pmid:7506456 |
| Gallon L et al. | Differential Effects of Calcineurin and Mammalian Target of Rapamycin Inhibitors on Alloreactive Th1, Th17, and Regulatory T Cells. | 2015 | Transplantation | pmid:25905982 |
| Fabrega AJ et al. | Enhancement of allograft survival by single intraoperative donor-specific blood transfusion combined with FK506. | 1993 | Transplantation | pmid:7506458 |
| Castells L et al. | Liver transplantation in HIV-HCV coinfected patients: a case-control study. | 2007 | Transplantation | pmid:17297413 |
| Burke MD et al. | Inhibition of the metabolism of cyclosporine by human liver microsomes by FK506. | 1990 | Transplantation | pmid:1700507 |
| Sharif A et al. | Insulin resistance indexes in renal transplant recipients maintained on tacrolimus immunosuppression. | 2010 | Transplantation | pmid:20145524 |
| Koh A et al. | Supplemental islet infusions restore insulin independence after graft dysfunction in islet transplant recipients. | 2010 | Transplantation | pmid:20145529 |
| Abu-Qaoud MS et al. | Lack of relationship between microvascular and macrovascular disease in heart transplant recipients. | 2012 | Transplantation | pmid:23044666 |
| Woodward RS et al. | Renal graft survival and calcineurin inhibitor. | 2005 | Transplantation | pmid:16177637 |
| Merkle M et al. | The effect of sevelamer on tacrolimus target levels. | 2005 | Transplantation | pmid:16177649 |
| Barten MJ et al. | Synergistic effects of sirolimus with cyclosporine and tacrolimus: analysis of immunosuppression on lymphocyte proliferation and activation in rat whole blood. | 2004 | Transplantation | pmid:15114077 |
| Moutabarrik A et al. | FK506-induced kidney tubular cell injury. | 1992 | Transplantation | pmid:1281562 |
| Vennarecci G et al. | Apoptosis and rejection in rat intestinal transplantation: correlation with FK506 doses and donor specific bone marrow infusions. | 2001 | Transplantation | pmid:11455248 |
| Schulman SL et al. | Interaction between tacrolimus and chloramphenicol in a renal transplant recipient. | 1998 | Transplantation | pmid:9625026 |
| Uemura T et al. | Single dose of alemtuzumab induction with steroid-free maintenance immunosuppression in pancreas transplantation. | 2011 | Transplantation | pmid:21841541 |
| Aw MM et al. | Calcineurin-inhibitor related nephrotoxicity- reversibility in paediatric liver transplant recipients. | 2001 | Transplantation | pmid:11544444 |
| Terakura M et al. | Lymphoid/nonlymphoid compartmentalization of donor leukocyte chimerism in rat recipients of heart allografts, with or without adjunct bone marrow. | 1998 | Transplantation | pmid:9721804 |
| Kai N et al. | Prevention of insulitis and diabetes in nonobese diabetic mice by administration of FK506. | 1993 | Transplantation | pmid:7682740 |
| Glicklich D et al. | Chronic renal allograft rejection: no response to mycophenolate mofetil. | 1998 | Transplantation | pmid:9721811 |
| Sulanc E et al. | New-onset diabetes after kidney transplantation: an application of 2003 International Guidelines. | 2005 | Transplantation | pmid:16249743 |
| Jacobson PA et al. | Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium. | 2011 | Transplantation | pmid:21206424 |
| Nolan TJ and Schad GA | Tacrolimus allows autoinfective development of the parasitic nematode Strongyloides stercoralis. | 1996 | Transplantation | pmid:8878405 |
| Eckhoff DE et al. | The safety and efficacy of a two-dose daclizumab (zenapax) induction therapy in liver transplant recipients. | 2000 | Transplantation | pmid:10830224 |
| Opelz G and Döhler B | Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. | 2009 | Transplantation | pmid:19300179 |
| Rostambeigi N et al. | Unique cellular and mitochondrial defects mediate FK506-induced islet β-cell dysfunction. | 2011 | Transplantation | pmid:21200364 |
| Mikhalski D et al. | Cold ischemia is a major determinant of acute rejection and renal graft survival in the modern era of immunosuppression. | 2008 | Transplantation | pmid:18401260 |
| Mazariegos GV et al. | Weaning of immunosuppression in liver transplant recipients. | 1997 | Transplantation | pmid:9020325 |
| Ericzon BG et al. | FK506-induced impairment of glucose metabolism in the primate--studies in pancreatic transplant recipients and in nontransplanted animals. | 1992 | Transplantation | pmid:1384189 |
| Nakazawa Y et al. | Relationship between in vivo FK506 clearance and in vitro 13-demethylation activity in living-related liver transplantation. | 1998 | Transplantation | pmid:9808496 |
| Krähenbühl S et al. | Serious interaction between mibefradil and tacrolimus. | 1998 | Transplantation | pmid:9808502 |
| Letavernier E et al. | Proteinuria following a switch from calcineurin inhibitors to sirolimus. | 2005 | Transplantation | pmid:16314786 |
| Komori K et al. | The role of graft and host accommodation in a hamster-to-rat cardiac transplantation model. | 2008 | Transplantation | pmid:18192920 |
| Wai LE et al. | Rapamycin, but not cyclosporine or FK506, alters natural killer cell function. | 2008 | Transplantation | pmid:18192925 |
| Jordan ML et al. | FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. | 1994 | Transplantation | pmid:7512293 |
| Yoshimura N et al. | A case report of pregnancy in renal transplant recipient treated with FK506 (tacrolimus). | 1996 | Transplantation | pmid:8633388 |